We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome. The median age at CLL and at HL diagnosis were 61 years (range 41-80) and 70 years (range 46-82), respectively, with a median interval from CLL to the diagnosis of HL of 90 months (range 0-258). In 3 cases, CLL and HL were diagnosed simultaneously. Hl was characterized by advanced stage in 79% of cases, International Prognostic Score (IPS) 4 in 50%, extranodal involvement in 39%, B symptoms in 70%. Prior treatment for CLL had been received by 82% of patients and included fludarabine in 67%. Coexistence of CLL and HL was detected in the same bioptic tissue in 87% of cases. The most common administered treatment was the ABVD regimen given to 22 patients (66.6%). The complete response (CR) rate after ABVD was 68%, and was influenced by the IPS (P 5 .03) and interval from the last CLL treatment (P 5 .057).
| I N T R O D U C T I O N
Richter syndrome (RS) defines the development of an aggressive lymphoma in the setting of chronic lymphocytic leukemia (CLL). 1 Two distinct variants of RS are recognized, diffuse large B-cell lymphoma (DLBCL-RS) and Hodgkin lymphoma (HL-RS). 2 DLBCL-RS is the most common type of RS observed in 2-7% of CLL patients included in clinical trials. [3] [4] [5] [6] [7] [8] Some genetic lesions-TP53, NOTCH1, MYC, CDKN2A
mutations-can predict the emergence of DLBCL-RS and are responsible for its aggressivity due to the combined effect of both chemoresistance and rapid disease kinetics. 3, [9] [10] [11] [12] [13] HL-RS variant is much less common since it is observed in 0.4%-0.7% of CLL patients. [14] [15] [16] [17] [18] [19] [20] While a clonal relationship between DLBCL-RS and CLL lymphocytes has been demonstrated in about 80% of patients, 9, 11, 12 only a limited number of HL-RS cases have been analyzed regarding their clonal relationship to CLL. By using microdissection and polymerase chain reaction amplification of the immunoglobulin heavy chain gene (IgH) complementarity determining region (CDR) III of each cell type, a same genetic origin of HL and CLL cells has been proven in some cases. [20] [21] [22] Prior published studies have shown that CLL patients who develop HL share the same adverse outcome than those with DLBCL-RS and also show a poorer survival than patients with de novo HL. 15, 16, 19 In particular, an inferior outcome has been described in patients with HL-RS who received a prior fludarabine-based treatment. 16, 19 Because of the rarity of this RS variant, little is known about the prognostic effect of CLL-related clinical and genetic factors. In addition, limited information is available regarding the treatment approach and response to therapy of CLL patients developing HL.
To improve the knowledge on this rare form of RS, we retrospectively collected and analyzed data on the clinical and biologic characteristics, response to treatment and outcome of 33 patients with CLL who developed HL-RS. 
| M E T H O D S

| Ethics
This retrospective, observational study was approved by the institutional review board and performed in accordance with the Declaration of Helsinki. The clinical and biologic characteristics of these patients are summarized in Table 1 . Briefly, the median age at CLL and at HL diagnosis The IGVH mutational status was available in 28 cases and in 18 (64.3%) was unmutated. Data about the IGVH family usage were available in 20 cases (Table 2 ; Supporting Information Figure S1 ).
FISH analysis was assessed at HL diagnosis in 23 patients and at CLL diagnosis in 2. No abnormalities were recorded in 52% of evaluated cases, while deletion 13q and trisomy 12, were both detected in 24%, of cases. Two patients revealed a TP53 aberration (deletion 17p
in one, TP53 mutation in one) ( Table 2) . The histologic pattern of HL was described as classic (cHL) in 29 cases (88%). The histologic subtype of cHL was unspecified in 16 cases (55%), while it was defined as mixed cellular in 7/13 (54%), lymphocyte rich in 3/13 (23%), nodular sclerosis in 2/13 (15%) and lymphocyte depleted in 1/13 (7%). A lymphocyte predominant histology was reported in 1 patient (3%), while in 3 cases no details about the histology were available.
| Clinical and histologic characteristics of HL
The immunohistochemical expression of EBV was tested in the biopsies of 17 patients and was positive in 13 (76%), 10 of which had been previously treated with fludarabine (Table 3 ).
Most of the 13 patients who had received CLL therapy within 12 months of HL-RS diagnosis showed an advanced Ann Arbor stage III-IV (11/13, 84%) an IPI 4 (7/12, 50%) and were IGVH unmutated (6/9, 67%).
In 20/23 (87%) cases the histologic and immunohistochemical data showed the coexistence of HL and CLL in the same biopsied tissue, while in 3 (13%) HL was detected in the lymph-node and CLL in the bone marrow. The coexistence of HL and CLL could not be evaluated in 8 cases (Supporting Information Table S1 ).
| Treatment of HL
The most common administered treatment was the ABVD regimen given to 22 patients (66.6%). Rituximab was combined with ABVD in 6
patients. The median number of administered courses of ABVD was 6
(range 2-6) with 12 patients (55%) receiving 6 courses. The causes of early treatment discontinuation were myelosuppression combined with A miscellanea of different chemotherapy regimens were administered to 6 patients (18%); 5 (15%) with clinically relevant comorbidities received palliative treatment with steroids only (Supporting Information   Table S2 ).
| Survival
Twenty-one patients died (64%). The cause of death was HL in 15 patients (71%), infection in 4 (19%) and heart failure in two (10%). The median survival from HL diagnosis was 37.8 months ( Figure 1A) Figure 1B ) and the IPS (median OS, IPS, <4 vs 4, 214 vs 6.8 months; P 5 .006; Figure 1C ). However, in multivariate analysis the achievement of a CR with ABVD emerged as the only significant and independent factor predicting survival (median OS, response to ABVD, RC vs no CR, 214 vs 6.8 months; P 5 .005, Figure 1D ; Supporting Information Table S4 ). HL has been described more frequently in CLL patients than in the general population. 27 Nonetheless, HL-RS is a rare event, about 10 times less frequent than that of the DBCL-RS variant. The rate of HL-RS cases observed in our study-0.7%-is in line with that reported at the Mayo Clinic by Parrick et al. 19 As only centers that observed at least one case of HL-RS participated in this study, the rate of cases of HL-RS variant could be overestimated. However, it should be also considered that as there is a close overlap of clinical signs between CLL and RS, and as the diagnosis of RS requires a biopsy, it is highly probable that many cases of RS may have been missed and classified as refractory CLL.
In about half of previously treated patients, the HL diagnosis was Institute. 15, 20 Similarly to elderly patients with de novo HL, 32, 33 patients with HL-RS showed frequently adverse clinical characteristics:
an Ann Arbor stage IV in 79% of cases, B symptoms in 70%, an extranodal involvement in 39%, a high IPS in 50%, and a mixed cellularity histology. 28 According to the available histological and immunohistochemical data, the coexistence of CLL and HL was described in all patients, in the same bioptic tissues in 87% of cases, and in two different biopsied sites in 13%. This was not an unexpected finding, as conventional treatments in CLL rarely induce long-term responses with no evidence of residual disease. In addition, about a third of patients showed an increased lymphocyte count at the time of HL diagnosis.
Due to the rarity of the HL-RS variant, and thus to the relatively small sample size, as well as to the retrospective nature of this study spanning over a 21-year period, we could not identify specific genetic lesions associated with the development of HL. A higher rate of IGHV unmutated than mutated cases was observed. The IGHV mutational status did not exert a significant effect on response to the ABVD nor a significant impact on survival. Other variables frequently observed in the DBCL-RS variant, 3, 12, 13 such as the presence of deletion 17p and TP53 mutations were reported only in 2 patients and trisomy 12 in 25% of cases.
Taking account of the coexistence of the two distinct types of lymphoproliferative disease, CLL and HL, and the lack of centralized pathological review there was some uncertainty about the prognostic value of the histologic subclassification of HL.
The immunohistochemical expression of EBV was detected in the majority of tested biopsies and most of positive patients had been previously treated with fludarabine. Several studies suggest that EBV is an important factor in the development of various lymphoproliferative disorders. 34 A close relationship between EBV infection and the development of HL has been reported in elderly patients with HL and in those with a mixed cellular histology. 35, 36 Based on the high rate of EBV positive cases, 9, [14] [15] [16] 20, 37 RS has been also considered as an EBV-related lymphoproliferative disorder triggered by the immunosuppressive effect induced by fludarabine. Interestingly, in this study the majority of patients with an EBV positive biopsy had been previously treated with fludarabine. However, a hypothetic relationship between fludarabine and RS was not confirmed by recent studies that evaluated the rate of RS cases according to the type of initial therapy. 38, 39 ABVD was the most common regimen administered to patients with HL-RS with a CR rate of 68% that is higher than that reported by The median survival from HL-RS diagnosis, 3.15 years, was comparable to that of patients with HL-RS described in prior studies, [18] [19] [20] but lower than that of elderly patients with de novo HL who show 5-year survival rates ranging between 58% and 65%. 19, 32, 33 The most frequent cause of death was HL itself, followed by infections, an expected adverse event in CLL patients.
Sixty-seven percent of patients had received a fludarabine-based regimen prior to the diagnosis of HL-RS. While in other studies 16, 19 prior therapy with purine analogs adversely impacted on the outcome of patients with HL-RS, in our study the same unfavorable effect did not emerge on the response to ABVD and survival.
We were able to effectively stratify the survival probability of patients with HL-RS according to four variables, the Hb value, the interval of time from the last CLL treatment, the IPS and the response to ABVD. As expected, a high IPS was associated with an inferior out- patients who achieved CR was over 17 years, it was only 7 months for those who failed to achieve a CR. Taken together, a high IPS and/or a short interval from the prior CLL treatment were associated with a lower chance of achieving a CR after ABVD, the most important factor that influenced survival of CLL patients with HL-RS.
In conclusion, this retrospective study shows that the HL-RS variant occurring in CLL is a rare event with a heterogeneous clinical course and prognostic features. Our data also indicate that the cure of HL-RS with ABVD is an attainable goal provided that patients show a low IPS and a late onset HL, diagnosed more than 12 months from the last CLL treatment.
